Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Oct 22 - Oct 27
Phase 3: The TRIUMPH Program (2023-Present) Program Design Following the compelling Phase 2 results, Eli Lilly advanced retatrutide into Phase 3 development under the TRIUMPH banner (Triple Receptor Agonist Intervention Utilizing Metabolic Pathways in Health)
Other pharmaceutical companies, including Neuraly, are testing GLP-1 drugs against Parkinsons disease
PMCID: PMC7040237
It is not known if Wegovy will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people Do not use Wegovy if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Do not use Wegovy if: you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy Before using Wegovy , tell your healthcare provider if you have any other medical conditions, including if you: have or have had problems with your pancreas or kidneys have type 2 diabetes and a history of diabetic retinopathy have or have had depression, suicidal thoughts, or mental health issues are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation) are pregnant or plan to become pregnant
